Sudeep Pharma Ltd

Sudeep Pharma Limited has announced the closure of its trading window for designated persons and their immediate relatives, effective October 1, 2026. This closure is in accordance with SEBI regulations and the company's code of conduct for preventing insider trading. The trading window will remain shut until 48 hours after the declaration of the un-audited financial results for the quarter and half-year ending September 30, 2026. The company will inform stock exchanges about the board meeting date to approve these financial results in due course.

Sudeep Pharma Ltd has issued a clarification regarding the number of attendees at its Annual General Meeting (AGM) held on August 4th, 2026. Previously reported as 45 attendees (5 from promoter group and 40 from public), the company has corrected this figure to 44 attendees (5 from promoter group and 39 from public). This correction pertains to the AGM Proceedings submission made on August 4th, 2026, and the E-voting Results submission on August 5th, 2026. The company requests that the corrected attendee number be taken on record.

Sudeep Pharma Limited announced that its Board of Directors, in a meeting held on August 4, 2026, has approved the Unaudited Standalone & Consolidated Financial Results for the first quarter ended June 30, 2026. The board meeting commenced at 3:40 p.m. and concluded at 5:50 p.m. The company's compliance officer, Dimple Mehta, submitted the financials. The review report from SR and Co. Chartered Accountants indicates that based on their review, nothing has come to their attention that causes them to believe the financial statements contain material misstatements, though two subsidiaries' results, amounting to ₹1,139.55 lakhs in revenue and ₹49.12 lakhs in net loss, were not reviewed and were deemed immaterial by management.

Sudeep Pharma Limited announced the outcome of its Board Meeting held on August 4, 2026. The Board considered and approved the Unaudited Standalone & Consolidated Financial Results for the first quarter ended June 30, 2026. The meeting commenced at 3:40 p.m. and concluded at 5:50 p.m. The limited review report on the consolidated financial results for the quarter ended June 30, 2026, was also presented. The results include financial data from two subsidiaries, which had a combined revenue of ₹1,139.55 lakhs and a net loss after tax of ₹49.12 lakhs before consolidation adjustments.

Nuvama Crossover Opportunities Fund, along with its Persons Acting in Concert (PACs), has disclosed a substantial acquisition of shares in Sudeep Pharma Limited. The acquisition, which occurred through a combination of preferential allotment (pre-IPO) and open market purchases (IPO), resulted in the fund holding 94,51,295 shares, representing 8.4% of the total share capital. The acquisition process spanned multiple dates, starting from July 9, 2024, and concluding with the IPO allotment date of November 27, 2025. This disclosure is made under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. Concurrently, the fund has also disclosed a sale of 26,68,118 shares, reducing its holding to 67,83,177 shares, or 6.0% of the total share capital.

Sudeep Pharma Ltd has announced that its Board of Directors will convene on August 4, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. In line with SEBI regulations, the company has closed its trading window from July 1, 2026, and it will reopen 48 hours after the financial results are declared, extending until August 6, 2026. This meeting is a routine procedural step for financial reporting.

Sudeep Pharma Ltd has announced Thursday, July 23, 2026, as the record date for determining shareholder eligibility for the final dividend for the financial year 2025-26. The Board of Directors had previously recommended a final dividend of ₹1.50 per equity share. This dividend is subject to approval at the 37th Annual General Meeting scheduled for Tuesday, August 4, 2026. Payment, after tax deduction, will be made to beneficial owners whose names appear in the depository records as of the close of business hours on the record date.

Sudeep Pharma Ltd has announced its 37th Annual General Meeting (AGM) scheduled for Tuesday, August 4, 2026, at 11:00 a.m. IST, to be held via Video Conferencing (VC) / Other Audio Visual Means (OAVM). The company is distributing its Integrated Annual Report for the Financial Year 2025-26 and the AGM Notice electronically to registered members. For shareholders whose email addresses are not registered, individual letters with web-links to these documents have been dispatched. Key dates for shareholders include the last date for TDS exemption forms (July 22, 2026), record date for final dividend (July 23, 2026), and remote e-voting period (August 1-3, 2026). Dividend payment is scheduled for August 7, 2026. Shareholders are urged to update their KYC details.

Sudeep Pharma Ltd has submitted its 37th Annual Report for the Financial Year 2025-26. The report details the company's performance, strategic priorities, and expansion into next-generation energy solutions, particularly battery materials through its subsidiary Sudeep Advanced Materials (SAMPL). The Annual General Meeting (AGM) is scheduled for Tuesday, August 4, 2026, at 11:00 A.M. via Video Conferencing. The report highlights a market capitalization of ₹6,693 crore as of March 31, 2026, and a final dividend of ₹1.50 per share. The company emphasizes its journey from mineral excipients for nutrition and pharmaceuticals to advanced materials for electric vehicles and energy storage.

Sudeep Pharma Ltd has announced its 37th Annual General Meeting (AGM) will be held on Tuesday, August 4, 2026, at 11:00 a.m. The meeting will be conducted through Video Conferencing (VC) or Other Audio-Visual Means (OAVM). The company is providing e-voting facilities through NSDL from August 1 to August 3, 2026. The cut-off date for voting eligibility is July 28, 2026. Key agenda items include the adoption of audited standalone and consolidated financial statements for FY 2025-26, the re-appointment of director Mr. Ajay Shrirang Kandelkar, and the declaration of a dividend of ₹1.50 per equity share for FY 2025-26.